Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

  • N. Raskin
  • , M. Hiligsmann
  • , A. R. Rebutoc
  • , N. Bansback
  • , A. Boonen
  • , R. Buchbinder
  • , M. Falahee
  • , L. Fraenkel
  • , D. A. Marshall
  • , L. Maxwell
  • , R. Nieuwlaat
  • , L. Proulx
  • , P. Saadat
  • , B. Shea
  • , P. Tugwell
  • , W. Wiercioch
  • , D. Beaton
  • , P. Richards
  • , H. Schünemann
  • , F. Guillemin
  • G. S. Hazlewood

Research output: Contribution to journalArticlepeer-review

5 Downloads (Pure)

Abstract

BACKGROUND: Interest in standardizing descriptions of health outcomes is increasing. In a Health Outcome Descriptor (HOD), outcomes are systematically described covering four domains: Symptoms, Time horizon, Testing and Treatment, and Consequences. Given the lack of HODs for Rheumatoid Arthritis (RA), the aim of this study was to review published RA outcome descriptions and map them to the HOD framework.

METHODS: We conducted a rapid review of patient-decision aids (PtDAs) and patient preference studies to assess how seven RA outcomes have been described in English to patients. These outcomes were selected by author consensus, from a living systematic review of RA drug therapy. After data extraction and a thematic content analysis, a narrative summary for each outcome was provided.

RESULTS: We included 11 PtDAs and 27 patient preference studies. Overall, the descriptions of the same health outcome varied widely across studies. Adverse events (AEs) were described in most cases (N = 26/38). For both PtDAs and preference studies, few provided a description for patient-important outcomes like remission (N = 2/11 and N = 1/27 respectively) and pain (N = 2/11 and N = 6/27 respectively). From an HOD perspective, the descriptions focused primarily on symptoms patients may experience (94 %), and less on the other domains (18-38 %).

CONCLUSION: There is wide variability in the content of the published RA outcome descriptions, as well as a lack of descriptions regarding common patient-important outcomes. As this study provides a detailed overview of existing descriptions, it may inform future development of HODs for RA.

Original languageEnglish
Article number152769
Number of pages10
JournalSeminars in arthritis and rheumatism
Volume74
Early online date6 Jun 2025
DOIs
Publication statusPublished - Oct 2025

Bibliographical note

Copyright © 2025 The Authors. Published by Elsevier Inc.

Keywords

  • Humans
  • Arthritis, Rheumatoid/drug therapy
  • Antirheumatic Agents/therapeutic use
  • Decision Support Techniques
  • Patient Preference
  • Patient Reported Outcome Measures
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors'. Together they form a unique fingerprint.

Cite this